- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06154044
Cell Therapy and Myocardial Recovery in Heart Failure Patients Undergoing Left Ventricular Assist Device Support (CELL-VAD)
The Effects of Cell Therapy on Myocardial Recovery in Chronic Heart Failure Patients Undergoing Left Ventricular Assist Device Support: A Pilot Trial (CELL-VAD Pilot)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
PROBLEM IDENTIFICATION Left ventricular assist device (LVAD) technology has evolved significantly and represents a standard of care for patients with advanced chronic heart failure. However, a significant discrepancy exists between structural and functional recovery of the failing myocardium, as only a small fraction (2%) of LVAD-supported patients demonstrate reverse structural remodeling and eventually reach clinically significant and stable functional improvement that allows for LVAD removal. Thus, there is a significant unmet need to define better the mechanisms of myocardial reverse remodeling in advanced chronic heart failure patients undergoing LVAD support.
OBJECTIVES
The goal of CELL-VAD Pilot trial is to investigate a personalized stem cell therapy approach for patients with advanced non-ischemic chronic heart failure (NICM) who are supported by LVAD. The investigators propose a Phase II non-randomized single-center clinical study focusing on (1) the administration of stem cell therapy that would allow for durable improvements in heart function and structure in NICM-LVAD patients. By using integrated analysis of multimodality imaging and biomarkers of fibrosis and angiogenesis, this project aims to (2) better define the pathophysiological mechanisms involved in myocardial recovery. Additionally, the investigators also aim to (3) define the safety parameters of stem cell therapy in NICM-LVAD patients. Based on these aims, the specific objectives of the CELL-VAD Pilot trial are:
The primary objective of this study is to investigate the safety and efficacy of stem cell therapy in NICM-LVAD patients, by evaluating changes in left ventricular structure and function, biomarkers of neurohormonal activation, patient exercise capacity, and clinical outcome.
The secondary objective of this study is to better define pathophysiological mechanisms involved in myocardial recovery in NICM-LVAD patients, by evaluating temporal changes in myocardial perfusion and in biomarkers of myocardial fibrosis in angiogenesis.
STUDY DESIGN The CELL-VAD Pilot trial consists of a clinical trial (WP1) and a multimodality imaging platform (WP2). The overall duration of the project is 3 years (36 months).
In the clinical trial, the investigators aim to enroll 10 patients with NICM, scheduled for LVAD implantation. After successful LVAD implantation, patients will be enrolled and followed for 2 months to allow for postoperative rehabilitation and heart failure medical therapy and LVAD support optimization. All patients will then undergo autologous CD34+ cell therapy which will be delivered via the intracoronary route. All patients will be followed for 6 months after cell therapy. At baseline, and at 1, 3, and 6 months after cell therapy, the investigators will perform comprehensive clinical evaluation. Clinical, biochemical, biomarker-related, imaging, and myocardial histology data will be transferred to a secured central database.
The investigators also aim to develop a personalized multimodality imaging platform by integrating the data obtained from advanced echocardiography and PET imaging.
EXPECTED OUTCOMES The investigators expect to demonstrate that in NICM-LVAD patients transendocardial autologous CD34+ cell therapy is safe and efficient, promoting the structural and functional reverse remodelling of the failing myocardium. Additionally, the results of this trial will establish a solid framework of knowledge and expertise for future clinical trials to build on.
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Gregor Poglajen, MD, PhD
- Phone Number: +38615228671
- Email: gregor.poglajen@kclj.si
Study Contact Backup
- Name: Mateja Lani
- Phone Number: +38615221163
- Email: mateja.lani@kclj.si
Study Locations
-
-
-
Ljubljana, Slovenia, 1000
- Recruiting
- University Medical Center Ljubljana
-
Contact:
- Gregor Poglajen, MD, PhD
- Phone Number: +38615228671
- Email: gregor.poglajen@kclj.si
-
Contact:
- Bojan Vrtovec, MD, PhD
- Phone Number: +38615221163
- Email: bojan.vrtovec@kclj.si
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Patient inclusion criteria will consist of all of the following:
- non-ischemic dilated cardiomyopathy
- patient accepted for LVAD support
- optimal (or maximal tolerable therapy) heart failure ≥ 2 months
- age 18-65 years
- ability to provide informed consent
Patient exclusion criteria will consist of any of the following:
- ischemic cardiomyopathy
- Cardiomyopathy with a reversible cause that has not been treated e.g. thyroid disease, alcohol abuse, hypophosphataemia, hypocalcaemia, cocaine abuse, selenium toxicity & chronic uncontrolled tachycardia.
- Cardiomyopathy in association with a neuromuscular disorder e.g. Duchenne's progressive muscular dystrophy.
- ongoing or recent (less than 1 month) infection
- acute multi-organ failure
- clinically significant anemia (Hb < 10 g/dL)
- clinically significant leukopenia (L < 2 x 109/L) or leukocytosis (L > 14 x 109/L)
- clinically significant thrombocytopenia (TRC < 50 x 109/L)
- known disorders of hemostasis that can not be corrected
- history of any thromboembolic complications
- chronic kidney disease (higher than stage III)
- chronic liver disease (Child B or C)
- diminished functional capacity for other reasons such as COPD, moderate or severe claudications, severe musculosceletal system pain or morbid obesity (BMI > 35 kg/m2)
- aortic stenosis (AVA < 1.3 cm2) or ocluded aortic valve
- artificial (mechanical or biological) aortic valve
- patients with reduced immune response
- history of limphoprolipherative disorders or malignancy within 5 years
- left ventricular thrombus
- participation in another interventional clinical trial
- life expectancy less than 12 months
- known hypersensitivity to DMSO, penicillin or streptomycin
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment Arm
After successful LVAD implantation, patients will be enrolled and followed for 2 months to allow for postoperative rehabilitation and heart failure medical therapy and LVAD support optimization.
All patients will then undergo autologous CD34+ cell therapy which will be delivered via intracoronary route.
All patients will be followed for 6 months after cell therapy.
At baseline, and at 1, 3 and 6 months after cell therapy, we will perform comprehensive clinical evaluation.
Clinical, biochemical, biomarker-related, imaging and myocardial histology data will be transferred to a secured central database.
|
After 5-days GCSF stimulation all patients will undergo apheresis to obtain CD34+ cell which will subsequently be injected in the target coronary artery using microcatheter.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
change in left ventricular ejection fraction (LVEF)
Time Frame: Baseline to 6 months
|
change in left ventricular ejection fraction (LVEF), measured by transthoracic echocardiography using Simpson's rule between the time of stem cell therapy and 6 months.
|
Baseline to 6 months
|
Changes in left ventricular end-systolic and end-diastolic dimensions
Time Frame: Baseline to 3 and 6 months
|
Changes in left ventricular end-systolic (LVESd) and end-diastolic dimensions (LVEDd) measured by transthoracic echocardiography in parasternal longitudinal axis with expected change > 10%.
|
Baseline to 3 and 6 months
|
Changes in left ventricular longitudinal and circumferential strains
Time Frame: Baseline to 3 and 6 months
|
Changes in left ventricular longitudinal and circumferential strains will be measured using transthoracic echocardiography and segmental wall motion analysis with expected change > 10%.
|
Baseline to 3 and 6 months
|
Changes in right ventricular size
Time Frame: Baseline to 3 and 6 months
|
Changes in right ventricular size (RVIDd) will be measured using transthoracic echocardiography with expected change > 10%.
|
Baseline to 3 and 6 months
|
Change in serum neurohumoral activation
Time Frame: Baseline to 3 and 6 months
|
Change in serum neurohumoral activation will be assessed measuring NT-proBNP serum levels, with expected decrease > 30%.
|
Baseline to 3 and 6 months
|
Changes in serum markers of fibrosis and angiogenesis
Time Frame: Baseline to 3 and 6 months
|
Changes in serum markers of fibrosis and angiogenesis will be assessed by measuring biomarkers of fibrosis and angiogenesis using Luminex commercially available kits (Human XL Cytokine Luminex® Performance Assay 46-plex); any detectable change will be considered a positive response.
|
Baseline to 3 and 6 months
|
Change in 6-minute walk test
Time Frame: Baseline to 3 and 6 months
|
Change in 6-minute walk test with expected increase > 30 m
|
Baseline to 3 and 6 months
|
Change in quality of life questionnaire score
Time Frame: Baseline to 3 and 6 months
|
Change in quality of life KCCQ questionnaire score with expected decrease of ≥ 5 points
|
Baseline to 3 and 6 months
|
Change in heart failure-related hospitalization
Time Frame: Baseline to 3 and 6 months
|
Change in heart failure-related hospitalization; any decrease will be considered
|
Baseline to 3 and 6 months
|
Collaborators and Investigators
Investigators
- Principal Investigator: Bojan Vrtovec, MD, PhD, UMC Ljubljana
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- UMC 1
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Heart Failure
-
Tufts Medical CenterMetro West Medical CenterCompletedCongestive Heart Failure | Diastolic Heart Failure | Systolic Heart FailureUnited States
-
Abbott Medical DevicesCompletedHeart Failure | Heart Failure, Diastolic | Heart Failure, Systolic | Heart Failure NYHA Class II | Heart Failure NYHA Class III | Heart Failure With Reduced Ejection Fraction | Heart Failure NYHA Class IV | Heart Failure With Normal Ejection Fraction | Heart Failure; With Decompensation | Heart Failure...United States, Canada
-
Manipal UniversityUnknownHeart Failure | Decompensated Heart Failure | Acute Heart Failure | Diastolic Heart Failure | Systolic Heart FailureIndia
-
VA Eastern Colorado Health Care SystemNational Institute on Aging (NIA)CompletedHeart Failure | Heart Failure, Diastolic | Heart Failure, Systolic | Heart Failure With Reduced Ejection Fraction | Heart Failure With Preserved Ejection Fraction | Heart Failure; With Decompensation | Heart Failure,Congestive | Heart Failure AcuteUnited States
-
University Hospital, MontpellierCompletedHeart Failure | Diastolic Heart Failure | Systolic Heart Failure Stage CFrance
-
Lancaster General HospitalLouise von Hess Medical Research InstituteEnrolling by invitationDiastolic Heart FailureUnited States
-
Wake Forest UniversityCompletedHeart Failure, Congestive | Heart Failure With Preserved Ejection Fraction
-
Wake Forest UniversityNational Institute on Aging (NIA)CompletedHeart Failure, Congestive | Diastolic Heart FailureUnited States
-
US Department of Veterans AffairsCompleted
-
Giresun UniversityIstanbul University - Cerrahpasa (IUC)RecruitingHeart Failure | Diastolic Heart Failure | Systolic Heart FailureTurkey
Clinical Trials on CD34+ stem cell therapy
-
China Medical University HospitalCompletedStroke | Middle Cerebral Artery InfarctionTaiwan
-
Diane GeorgeActive, not recruitingSickle Cell Disease | Hemoglobinopathies | Severe Congenital Neutropenia | Diamond-Blackfan Anemia | Severe Aplastic Anemia | Macrophage Activation Syndrome | Bone Marrow Failure Syndrome | Amegakaryocytic Thrombocytopenia | Schwachman Diamond Syndrome | Primary Immunodeficiency Syndromes | Acquired Immunodeficiency... and other conditionsUnited States
-
China Medical University HospitalUnknownIschemia | Ischemic Stroke | Brain Ischemia | Infarction, Middle Cerebral Artery | Ischaemic Cerebral InfarctionTaiwan
-
Shenzhen Second People's HospitalGuangzhou Women and Children's Medical Center; Shenzhen UniversityRecruitingAdrenoleukodystrophy | Metachromatic LeukodystrophyChina
-
Hospital Universitario Dr. Jose E. GonzalezSuspendedCardiomyopathy, DilatedMexico
-
M.D. Anderson Cancer CenterRecruitingBlood And Marrow TransplantationUnited States
-
Christopher DvorakNo longer availableAcute Myeloid Leukemia | Leukocyte Disorders | Acute Lymphoblastic Leukemia | Chronic Myeloid Leukemia | Myelodysplastic Syndrome | Cytopenias | Immune Deficiency | Lymphomas | Bone Marrow Failure | Osteopetrosis | Hemoglobinopathy | Anemia Due to Intrinsic Red Cell AbnormalityUnited States
-
University Medical Centre LjubljanaStanford University; Blood Transfusion Centre of SloveniaCompletedDilated CardiomyopathySlovenia
-
Losordo, Douglas, M.D.CompletedMyocardial Ischemia | Chest Pain | Heart Disease | Angina | Coronary Arterial Disease (CAD)United States
-
The Emmes Company, LLCNational Eye Institute (NEI); University of California, DavisActive, not recruitingCentral Retinal Vein OcclusionUnited States